Estrella Immunopharma (ESLA) Change in Cash (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Change in Cash of $543102.0 for Q1 2026, up 209.62% year-over-year from $175409.5 in Q1 2025, and up 324.14% quarter-over-quarter from -$242308.0 in Q4 2025.
Estrella Immunopharma (ESLA) Change in Cash (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Change in Cash for 6 consecutive years, with $543102.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Cash rose 209.62% year-over-year to $543102.0; the TTM figure through Mar 2026 stood at $1.5 million (up 109.49% YoY), while the FY2025 annual figure was $467386.0, up 105.75% from the prior year.
- Change in Cash climbed to $543102.0 in Q1 2026 per ESLA's latest filing, from -$242308.0 in the prior quarter.
- Across five years, Change in Cash topped out at $19.7 million in Q3 2023 and bottomed at -$7.2 million in Q3 2024.
- Historically, Change in Cash has averaged $626683.8 across 5 years, with a median of -$242308.0 in 2025.
- Annual changes were most pronounced in 2023 — Change in Cash soared 1886.8% — and 2024, when it tumbled 79726.41%.
- Estrella Immunopharma's Change in Cash stood at -$1.2 million in 2022, then jumped by 1243.26% to $13.8 million in 2023, then slumped by 123.51% to -$3.2 million in 2024, then soared by 92.54% to -$242308.0 in 2025, then surged by 324.14% to $543102.0 in 2026.
- Business Quant data shows ESLA's Change in Cash at $543102.0 in Q1 2026, -$242308.0 in Q4 2025, and $310016.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - | -1.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.78 Mn |
| Mar 31, 2026 | 543,102.00 |
| Dec 31, 2025 | -242,308.00 |
| Sep 30, 2025 | 310,016.00 |
| Jun 30, 2025 | 895,121.00 |
| Mar 31, 2025 | -495,443.00 |
| Dec 31, 2024 | -3.25 Mn |
| Sep 30, 2024 | -7.25 Mn |
| Jun 30, 2024 | -4.88 Mn |
| Mar 31, 2024 | -4.32 Mn |
| Dec 31, 2023 | 13.82 Mn |
| Sep 30, 2023 | 19.66 Mn |
| Jun 30, 2023 | -6,114.00 |
| Mar 31, 2023 | -1.43 Mn |
| Dec 31, 2022 | -1.21 Mn |
| Sep 30, 2022 | -1.10 Mn |
| Jun 30, 2022 | -233,443.00 |
| Mar 31, 2022 | -157,144.00 |
| Dec 31, 2021 | -293,300.00 |
| Sep 30, 2021 | 761,150.00 |